HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Paul W O'Connor Selected Research

natalizumab (Tysabri)

11/2015Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update.
5/2013Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.
8/2011Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.
8/2011Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
5/2011The toronto observational study of natalizumab in multiple sclerosis.
9/2010Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
5/2010Increasing use of disease modifying drugs for MS in Canada.
1/2010Use of natalizumab in multiple sclerosis patients.
3/2009The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
3/2009Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Paul W O'Connor Research Topics

Disease

26Multiple Sclerosis
11/2015 - 01/2003
7Relapsing-Remitting Multiple Sclerosis
10/2014 - 05/2007
2Disease Progression
07/2014 - 05/2010
2Inflammation
01/2012 - 01/2009
2Progressive Multifocal Leukoencephalopathy
08/2011 - 09/2010
1Respiratory Tract Infections (Respiratory Tract Infection)
10/2014
1Human Influenza (Influenza)
08/2013
1Neurodegenerative Diseases (Neurodegenerative Disease)
01/2012
1Heart Failure
05/2010
1Leukemia
05/2010
1Opportunistic Infections (Opportunistic Infection)
05/2007
1Hypersensitivity (Allergy)
03/2006
1Fatigue
03/2006
1Body Weight (Weight, Body)
01/2003
1Chronic Progressive Multiple Sclerosis
01/2003

Drug/Important Bio-Agent (IBA)

14natalizumab (Tysabri)FDA Link
11/2015 - 01/2003
7teriflunomideIBA
10/2014 - 09/2012
3interferon beta 1aFDA Link
02/2012 - 10/2007
2SteroidsIBA
01/2012 - 01/2009
2copolymer 1 (glatiramer acetate)FDA Link
09/2010 - 05/2010
1Alanine Transaminase (SGPT)IBA
10/2014
1Biological Markers (Surrogate Marker)IBA
07/2014
1Influenza Vaccines (FluMist)IBA
08/2013
1AntibodiesIBA
08/2013
1MethylprednisoloneFDA LinkGeneric
01/2012
1DNA (Deoxyribonucleic Acid)IBA
09/2010
1InterferonsIBA
09/2010
1Mitoxantrone (Novantrone)FDA LinkGeneric
05/2010
1interferon beta-1b (Betaseron)FDA Link
05/2010
1Interferon-betaIBA
03/2009
14-Aminopyridine (4 Aminopyridine)IBA
11/2008
1Integrin alpha4IBA
01/2003

Therapy/Procedure

2Therapeutics
02/2015 - 05/2010
1Injections
09/2010